Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients ( ≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study.

CONCLUSIONS: Ustekinumab effectively treated moderate-to-severe psoriasis in pediatric patients, and no new safety concerns were identified.
PMID: 32173852 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - March 15, 2020 Category: Dermatology Authors: Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, Song M, Randazzo B, Li S, Hsu MC, Zhu Y, DePrimo S, Paller AS Tags: Br J Dermatol Source Type: research